Citi analyst Yigal Nochomovitz has maintained their bullish stance on ZLAB stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yigal Nochomovitz has given his Buy rating due to a combination of factors related to Zai Lab’s recent clinical trial outcomes and future potential. The announcement of the successful interim results from the Phase 3 FORTITUDE-101 trial, which led to the early termination of the study due to significant efficacy, is a crucial factor. This outcome suggests a promising future for Zai Lab’s product in treating FGFR2b+ gastric cancer, despite some concerns about ocular adverse events that need further clarification.
Additionally, Nochomovitz maintains a positive outlook on the probability of success for bemarituzumab, with a 70% chance of success in the targeted cancer treatment. The anticipation of further data from another Phase 3 trial, FORTITUDE-102, which is expected to report in the second half of 2025, also supports the Buy rating. The expected share price return of 87.2% further underscores the positive sentiment and potential for significant investment returns.
According to TipRanks, Nochomovitz is a 4-star analyst with an average return of 3.4% and a 38.98% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Travere Therapeutics, and Arcturus Therapeutics.